A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 760 participants.

Also called NCT07421297

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 760 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07421297
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07421297. Randomized; quadruple masking; primary purpose treatment. Start 2026-02-28 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia
Condition
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
Intervention (Drug)
SYH2053 injection
Intervention (Other)
SYH2053 injection placebo
Lead sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07421297
Content hash
c4f861fc902080cb5a7502bb422c9ee4ef5c96f5ad96cb6e140356b7201f3203